Biotronik Announces Additional Investment in Magmaris Resorbable Magnesium Scaffold

May 23, 2018—Biotronik announced that it will further invest in the company’s Magmaris resorbable magnesium scaffold (RMS) as additional data continue to support the scaffold’s safety and efficacy.

Outcomes data from the first 200 patients of the 1,065-patient cohort included in the BIOSOLVE-IV registry were presented by Stefan Verheye, MD, during EuroPCR 2018, held May 21–25 in Paris, France. The data show comparable target lesion failure rates (4.6%) to second-generation drug-eluting stents at 12 months and only one case of scaffold thrombosis (after dual antiplatelet therapy interruption before the event). Dr. Verheye is Senior Interventional Cardiologist at Antwerp Cardiovascular Institute, in Antwerp, Belgium.

These promising results also included patients with non–ST-segment elevation myocardial infarction (14.5%), a challenging patient group.

“The new data give insights in a more complex population and add to the body of evidence supporting the efficacy of Magmaris,” commented Michael Kang-Yin Lee, MD, in the company’s announcement. Dr. Kang-Yin Lee is the Honorary Clinical Associate Professor of the University of Hong Kong and Consultant Cardiologist at Queen Elizabeth Hospital in Hong Kong, China, as well as Principal Investigator of the BIOSOLVE-IV study.

Additionally, new 3-year data from BIOSOLVE-II on optical coherence tomography were presented by Michael Joner, MD, Professor in Interventional Cardiology at the German Heart Center in Munich, Germany. These data confirmed previous preclinical findings on Magmaris that showed reduced signs of neoatherosclerosis, a possible complication of permanent implants.

“This investment [in magnesium as a scaffold material] underlines [Biotronik’s] belief that the RMS has a significant role to play in interventional cardiology,” said Alexander Uhl, MD, Senior Vice President of Corporate Marketing at Biotronik in the company’s announcement. “We firmly expect that evidence will support the relevance of the RMS in wider indications and patient populations.”